Fundz

Vyriad secures final $25M Series B tranche, totaling $85M, to advance its in vivo CAR T candidate into clinic, led by Harry Stine.

PRIVATEDec 23, 2025

Amount Raised

$25 Million

Round Type

Series B

RochesterBiotechnologyHealth CareScience And Engineering

Investors

Stine Seed FarmsStine Seed Farms, Inc.Harry Stine

Description

Vyriad, Inc. has announced the closing of a $25M final tranche to its Series B financing, increasing the total to $85M. This funding supports the imminent first-in-human testing of its in vivo CAR T candidate, VV169. The round was led by Harry Stine of Stine Seed Farms, with participation from several significant family offices

Quick answer

Vyriad raised $25 Million in a Series B round, dated December 23, 2025. Investors: Stine Seed Farms, Stine Seed Farms, Inc. and Harry Stine. Vyriad is based in Rochester, New York, United States.

How much did Vyriad raise?
Vyriad raised $25 Million in a Series B round on December 23, 2025.
Who invested in Vyriad?
Stine Seed Farms, Stine Seed Farms, Inc. and Harry Stine are named as investors in this round.
What does Vyriad do?
Vyriad is a clinical-stage biotechnology company developing targeted genetic medicines for cancer and other serious diseases.
Where is Vyriad based and how big is it?
Vyriad is based in Rochester, New York, United States. Fundz records about 52 employees.
Who are the decision-makers at Vyriad?
Fundz holds 2 contacts at Vyriad, including the EVP. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Science And Engineering and Biotechnology around the same time

Companies in the same sectors as Vyriad that raised within 45 days of this round, from Fundz verified event records.

  • Enveric Biosciences raised $1.5M on January 28, 2026.
  • PrognomiQ raised $12M on January 2, 2026.
  • MAIA Biotechnology raised $1.5M on December 22, 2025.
  • Atavistik Bio raised $120M (Series B) on December 21, 2025.
  • Enveric Biosciences raised $107K on December 12, 2025.
  • Aprea Therapeutics raised $3.1M on December 10, 2025.

Who to call at Vyriad, and when

A new round usually means Vyriad is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Vyriad raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Vyriad, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Vyriad. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Vyriad

Location

2900 37th Street NW

Rochester, New York, United States

About

Vyriad is a clinical-stage biotechnology company developing targeted genetic medicines for cancer and other serious diseases. The company uses engineered viruses, viral vectors, and viral envelope glycoproteins to deliver therapeutic genes directly to selected cells. It has ongoing corporate partnerships with Regeneron Pharmaceuticals and Novartis. Vyriad’s developmental programs include oncolytic virotherapy, in vivo gene therapy, and gene-editing applications, with ongoing Phase 1–2 trials across multiple cancer indications. Vyriad is a privately held company based in Rochester, Minnesota and was co-founded by Mayo Clinician-Scientists, Dr. Stephen Russell and Dr. Kah-Whye Peng, to further develop and bring into clinical trials a set of research breakthroughs in their gene and virus therapy research labs.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Vyriad raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsLuke R., EVPSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Vyriad's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Vyriad raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.